MD Anderson study points to potential new lung cancer therapy

(University of Texas M. D. Anderson Cancer Center) New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, has shown therapeutic promise for several cancers, including the most common form of lung cancer.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

This study suggests that the U11-DOX/CUR NPs have promising potential for combination treatment of lung cancer.Graphical abstract
Source: Biomedicine and Pharmacotherapy - Category: Drugs & Pharmacology Source Type: research
Conclusion: Maintenance therapy in NSCLC continues to be an important therapeutic line to improve outcome in patients with metastatic and recurrent disease.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
hamed El-Tanani The delivery of anticancer agents to their subcellular sites of action is a significant challenge for effective cancer therapy. Peptides, which are integral to several oncogenic pathways, have significant potential to be utilised as cancer therapeutics due to their selectivity, high potency and lack of normal cell toxicity. Novel Ras protein-Regulator of chromosome condensation 1 (Ran-RCC1) inhibitory peptides designed to interact with Ran, a novel therapeutic target in breast cancer, were delivered by entrapment into polyethylene glycol-poly (lactic-co-glycolic acid) PEG-PLGA polymeric nanoparticles (N...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Abstract OBJECTIVE: Wearable devices such as a wrist actigraph may have a potential to objectively estimate patients' functioning and may supplement performance status (PS). This proof-of-concept study aimed to evaluate whether actigraphy data are significantly associated with patients' functioning and are predictive of their survival in patients with metastatic non-small cell lung cancer. METHOD: We collected actigraphy data for a three-day period in ambulatory patients with stage IV non-small cell lung cancer. We computed correlations between actigraphy data (specifically, proportion of time spent immobile ...
Source: Palliative and Supportive Care - Category: Palliative Care Authors: Tags: Palliat Support Care Source Type: research
hler Non-small cell lung cancer (NSCLC) in non-, and especially in never-smoking patients is considered a biologically unique type of lung cancer, since risk factors and tumorigenic conditions, other than tobacco smoke, come into play. In this review article, we comprehensively searched and summarized the current literature with the aim to outline what exactly triggers lung cancer in non-smokers. Changes in the tumor microenvironment, distinct driver genes and genetic pathway alterations that are specific for non-smoking patients, as well as lifestyle-related risk factors apart from tobacco smoke are critically discuss...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
In the present study, we conducted high ‐throughput luciferase reporter screening to discover new Keap1/Nrf2 pathway inhibitors. From our screening, the novel compound K‐563 was isolated from the culture broth ofStreptomyces sp. 3728 ‐17 and was found to selectively inhibit the reporter activity of the Keap1/Nrf2 pathway. Furthermore, K‐563 inhibited the expression of Keap1/Nrf2 pathway downstream proteins, GSH synthesis and ROS resistance through the suppression of the Keap1/Nrf2 pathway downstream gene expression. AbstractKeap1/Nrf2 pathway regulates the antioxidant stress response, detoxification response, and e...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Abstract The evolution of therapeutic resistance is a major cause of death for cancer patients. The development of therapy resistance is shaped by the ecological dynamics within the tumor microenvironment and the selective pressure of the host immune system. These selective forces often lead to evolutionary convergence on pathways or hallmarks that drive progression. Thus, a deeper understanding of the evolutionary convergences that occur could reveal vulnerabilities to treat therapy-resistant cancer. To this end, we combined phylogenetic clustering, systems biology analyses, and molecular experimentation to ident...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Med Source Type: research
Abstract Telomerase is an important biomarker for cancer diagnosis and a valuable target for cancer therapy. Most of the reported telomerase assays suffer from the repeating thermal cycles, laborious protocols, expensive instruments and the limited sensitivity. To solve these issues, we develop a new telomerase assay based on telomerization-driven release of fluorescent 2-aminopurine. We designed a 2-aminopurine molecular beacon in which the fluorescence of 2-aminopurine is quenched due to stacking interaction effect without the use of extra quenchers. The presence of target telomerase can open the 2-aminopurine m...
Source: Analytica Chimica Acta - Category: Chemistry Authors: Tags: Anal Chim Acta Source Type: research
In this study, CAR vectors were constructed and transfected into virus-packaging cells. Then, activated T cells were infected with retrovirus harvested from stable virus-producing single clone cell lines. CAR expression on the surfaces of the T cells was detected by flow cytometry andWestern blot. The function of CAR-T targeting EGFRvIII was then evaluated. The EGFRvIII-CAR vector was successfully constructed and confirmed by DNA sequencing. A stable virus-producing cell line was produced from a single clone by limited dilution. The culture conditions for the cell line, including cell density, temperature, and culture medi...
Source: Frontiers of Medicine - Category: General Medicine Source Type: research
CONCLUSION: In summary, these findings suggest that targeting EndMT through GSK-3β inhibition in HUVECs might represent a promising therapeutic strategy for lung cancer therapy. PMID: 30709379 [PubMed - in process]
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Tags: J Exp Clin Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Lung Cancer | Study | Texas University